Inmune Bio (INMB) Share-based Compensation (2018 - 2026)
Inmune Bio (INMB) posted Share-based Compensation of $8.4 million for Q1 2026, up 500.86% sequentially from $1.4 million in Q4 2025, and up 304.62% YoY from $2.1 million in Q1 2025.
Inmune Bio (INMB) Share-based Compensation (2018 - 2026) Analysis & Trends
Inmune Bio has reported Share-based Compensation for 9 years, with the latest figure at $8.4 million in Q1 2026.
- Quarterly Share-based Compensation rose 304.62% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 6.3% YoY) and the FY2025 annual result came in at $10.0 billion, up 131037.41% from the prior year.
- Share-based Compensation climbed to $8.4 million in Q1 2026 per INMB's latest filing, from $1.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $8.4 million in Q1 2026 and troughed at $1.4 million in Q4 2025.
- A 5-year average of $2.6 million and a median of $1.9 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation sank 58.13% in 2022, then jumped 365.39% in 2025.
- Over 5 years, Share-based Compensation stood at $1.7 million in 2022, then gained by 7.43% to $1.9 million in 2023, then decreased by 6.49% to $1.8 million in 2024, then slipped by 20.43% to $1.4 million in 2025, then jumped by 500.86% to $8.4 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $8.4 million, $1.4 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 7.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.10 Mn |
| Jun 30, 2026 | 7.10 Mn |
| Mar 31, 2026 | 8.40 Mn |
| Mar 31, 2026 | 8.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | 2.08 Mn |
| Mar 31, 2025 | 2.08 Mn |
| Dec 31, 2024 | 1.76 Mn |
| Dec 31, 2024 | 1.76 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Mar 31, 2024 | 1.78 Mn |